RENOVA (tretinoin emollient cream) 0.05% contains the active ingredient tretinoin (a retinoid) in an emollient cream base. Tretinoin is a yellow to light orange crystalline powder having a characteristic floral odor. Tretinoin is soluble in dimethylsulfoxide, slightly soluble in polyethylene glycol 400, octanol, and 100% ethanol. It is practically insoluble in water and mineral oil, and it is insoluble in glycerin. The chemical name for tretinoin is (all-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclonexen-1-yl)-2,4,6,8-nonatetraenoic acid.
RENOVA (tretinoin emollient cream) 0.05% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of
wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who do not achieve such palliation using comprehensive skin care and sun avoidance programs alone (see bullet point 3 for populations in which effectiveness has not been established). RENOVA DOES NOT ELIMINATE WRINKLES, REPAIR SUN DAMAGED SKIN, REVERSE PHOTO-AGING, or RESTORE A MORE YOUTHFUL or YOUNGER DERMAL HISTOLOGIC PATTERN. Many patients achieve desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sun avoidance programs including sunscreens, protective clothing, and emollient creams
RENOVA has demonstrated NO MITIGATING EFFECT on significant signs of chronic sun exposure such as
wrinkling, skin yellowing, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis.
RENOVA should only be used under medical supervision as an adjunct to a comprehensive skin care and sun avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing when desired results on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin have not been achieved with a comprehensive skin care and sun avoidance program alone.
The effectiveness of RENOVA in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin has not been established in people greater than 50 years of age OR in people with moderately to heavily pigmented skin. In addition, patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA. Thus the effectiveness and safety of RENOVA in these populations are not known at this time.
Neither the safety nor the effectiveness of RENOVA for the prevention or treatment of actinic keratoses or skin neoplasms has been established.
Neither the safety nor the efficacy of using RENOVA daily for greater than 48 weeks has been established, and daily use beyond 48 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.)
Published Studies Related to Renova (Tretinoin)
Tretinoin cyclodextrin complex (RA/CyD) causes less irritation with an equal
antiwrinkle effect compared with conventional tretinoin: clinical and histologic
studies of photoaged skin. 
the side effects compared with RA treatment alone... CONCLUSION: The findings show that RA and RA/CyD result in the equivalent
A randomized, double-blind, placebo-controlled, pilot study to assess the
efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for
the treatment of acne rosacea over 12 weeks. 
rosacea after 12 weeks of usage... CONCLUSIONS: A combination gel of clindamycin phosphate 1.2% and tretinoin 0.025%
A randomized, double-blind, controlled comparative trial of the anti-aging
properties of non-prescription tri-retinol 1.1% vs. prescription tretinoin
Vitamin A and its derivatives (commonly termed retinoids) are widely used in
topical anti-aging products. Certain retinoids such as retinol and its esters are
available without a prescription, while others such as tretinoin are available
only via prescription... Subjects reported >93 percent overall satisfaction with
both products at weeks 8 and 12.
Further enhancement of facial appearance with a hydroquinone skin care system plus tretinoin in patients previously treated with botulinum toxin Type A. [2011.07]
BACKGROUND: A hydroquinone (HQ) skin care system has been designed for use in conjunction with nonsurgical procedures. OBJECTIVE: The authors evaluate the efficacy of this system plus tretinoin for improving facial appearance in comparison to a standard skin care regimen in users of botulinum toxin Type A (BoNT-A)... CONCLUSIONS: Adjunctive use of the HQ system plus tretinoin can further enhance the improvements in facial appearance attained with BoNT-A. Applying the HQ system plus tretinoin offers multiple clinical benefits over standard skin care, including significantly greater improvements in fine lines/wrinkles and hyperpigmentation.
Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. [2011.07]
BACKGROUND: Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17alpha-propionate (CB-03-01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris. OBJECTIVES: To evaluate the safety and the topical efficacy of CB-03-01 1% cream in acne vulgaris as compared with placebo and with tretinoin 0.05% cream (Retin-A(R) ; Janssen-Cilag)... CONCLUSIONS: This pilot study supports the rationale for the use of topical antiandrogens in the treatment of acne vulgaris. CB-03-01 1% cream seems to fit with the profile of an ideal antiandrogen for topical use. (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
Clinical Trials Related to Renova (Tretinoin)
Post-Approval Study for the FLAIR Endovascular Stent Graft [Recruiting]
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes [Recruiting]
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop
the growth of myelodysplastic cells, either by killing the cells or by stopping them from
dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal
cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be
an effective treatment for myelodysplastic syndromes.
PURPOSE: This phase I/II trial is studying the side effects and best dose of tretinoin when
given together with decitabine in treating patients with myelodysplastic syndromes.
Study to Compare the Acne Relapse Rate of Oral Minocycline to Oral Minocycline in Combination With Topical Tretinoin, Followed by Topical Tretinoin Alone [Recruiting]
The use of oral antibiotics alone to treat inflammatory acne provides little to no long term
Acne relapse rates can be reduced by using topical tretinoin 0. 01% in conjunction with
minocycline, thereby increasing the therapeutic effect of the oral antibiotic.
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer [Active, not recruiting]
One-third of all malignancies in the United States (approximately one million cases diagnosed
annually) are nonmelanoma skin cancer (NMSC). NMSC causes considerable morbidity, economic
burden, facial deformity and at least 1,000 deaths annually. Prevention of these malignancies
with a topical agent free of serious side effects would confer substantial public health
benefit. Three hundred fifty thousand veterans were expected to develop NMSC in 1994. NMSC is
one of the most common conditions requiring dermatologic care in the VA system. Topical
tretinoin has been used extensively to treat photoaged skin. Retinoids administered orally in
high doses appear to be effective in chemoprevention of nonmelanoma skin cancer but have
unacceptable toxicity. In this study, 1131 patients with a recent history of squamous cell
and/or basal cell carcinoma were enrolled at six participating centers over a four-year
period and were randomly assigned to either 0. 1% tretinoin cream or placebo. They were
followed for a minimum of two years to determine if topical tretinoin is effective in
reducing the risk of new occurrences.
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia [Recruiting]
RATIONALE: Tretinoin may help cancer cells become more like normal cells, and to grow and
spread more slowly. Drugs used in chemotherapy, such as arsenic trioxide and idarubicin, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving tretinoin together with arsenic trioxide with or without
idarubicin may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving tretinoin together with arsenic
trioxide with or without idarubicin works in treating patients with acute promyelocytic
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 34 ratings/reviews, Renova has an overall score of 6.88. The effectiveness score is 6.76 and the side effect score is 7.06. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Renova review by 24 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || acne|
|Dosage & duration:|| || .025 (dosage frequency: every now and then) for the period of 2 years|
|Other conditions:|| || none|
|Other drugs taken:|| || retin-A|
|Benefits:|| || good for skin|
|Side effects:|| || none|
|Comments:|| || take alongside .05 retin-A treatment alternative, good stuff|
Renova review by 43 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || melasma|
|Dosage & duration:|| || 0.025% (dosage frequency: once per day) for the period of 4 weeks|
|Other conditions:|| || wrinkles|
|Other drugs taken:|| || Hydroquinone|
|Benefits:|| || Faint pigmentation started to disappear after ten days of use, and dark ones continued to become lighter. Overall, skin became smoother and lighter after cleansing.|
|Side effects:|| || Sever redness and scaling occurred especially around the chin and the cheek, which could not be covered with makeup. Mild itching sensation was a little disturbing to focus at work.|
|Comments:|| || Applied at night, after cleansing the face, more than thirty minutes before going to bed. Used ~1 cm of the cream for entire face and neck, followed with 4% Hydroquinone solution. When swelling occurred, application was omitted until it disappears, which usually took place in 24 hours.|
Renova review by 52 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Marginally Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || anti aging|
|Dosage & duration:|| || .05 (dosage frequency: every day) for the period of two years|
|Other conditions:|| || wrinkles|
|Other drugs taken:|| || none|
|Benefits:|| || At first, there was some minor improvement in the texture of my skin but then it began to degrade the area around my eye. The skin became thinner in appearance and more and more dry. It seemed to be harming my skin. At that point my dermotologist said my skin may be too sensitive. I do not feel that I have sensitive skin because while I may have a pale color skin, it has a olive tone. I do not sunburn very easily. Then I switched to ROC but had similar results.|
|Side effects:|| || Dry and thinning skin.|
|Comments:|| || I followed the directions which were to increase it gradually.
Another drug that I have had success with is hydroquinone. It does bleach out my melasma very well but it takes perservance and regularity in its application.|
Page last updated: 2013-02-10